Therefore, in this study, we investigated the antiobesity and anti-metabolic syndrome effects of SW20.1 and ST32db in mice with HFD-induced obesity and explored whether the molecular mechanism of SW20.1 involves the ATF3-medicated signaling pathway. Here, ATF3 is linked to obesity disorder.